Evaluation of the Safety and Effectiveness of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Phase IV Non-interventional Post-marketing Surveillance Study in India

Trial Profile

Evaluation of the Safety and Effectiveness of BOTOX (Botulinum Toxin Type A) in the Treatment of Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Phase IV Non-interventional Post-marketing Surveillance Study in India

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 21 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 22 Apr 2017 Planned End Date changed from 1 Jun 2017 to 19 Sep 2017.
    • 22 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 8 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top